Yungjin Pharmaceutical Co. Ltd.

Industry

  • Pharmaceuticals
    • Vaccines
    • Specialty Pharmaceuticals
    • Generic Drugs

Other Names/Subsidiaries

  • KT&G Corporation
  • Mazence Inc.
  • KT&G Life Sciences Corp.
See more in Biomedtracker

Latest on Yungjin Pharmaceutical Co. Ltd.

In Vivo

Deals Shaping The Medical Industry, June 2017

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

IN VITRO DIAGNOSTICS Financings Accelerate Diagnostics Inc. Infectious disease-focused Accelerate Diagnostics Inc. netted $74.6mm through the upsized follow-on offering of 2.75mm common shares pri

Scrip

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

 
• By Joseph Haas, Ian Haydock, Jung Won Shin, Brian Yang, and Lubna Ahmed

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Pink Sheet

Korean Pro-Innovation Pricing Steps Draw Mixed Responses

 
• By Jung Won Shin

SEOUL - South Korea will raise the prices of “global innovative novel drugs” and biomedicines, and shorten the period before national health insurance listing, to provide incentives for R&D spending a

Scrip

Global Phase III programme for D-Pharm's neurorotective extended to S Korea

 
• By Ian Haydock

D-Pharm's local licensee Yungjin Pharmaceutical has received approval from South Korea's FDA to begin a Phase III trial in the country with D-Pharm's neuroprotective and lead product candidate DP-b99.